Strategic launches Solaris recently expanded its portfolio with brivaracetam tablets, a generic version of Briviact, signaling readiness to capitalize on high-value epilepsy therapy opportunities and potentially cross-sell related complex generics.

Specialty focus The company concentrates on complex generics and specialty medicines across sterile, dermatological, and solid oral forms, presenting multiple avenues to target niche markets with high unmet needs.

Rapid development With integrated R&D, regulatory strategy, and commercialization capabilities, Solaris emphasizes streamlined development timelines and cost efficiencies, enabling faster time-to-market for new products and expanded pipeline opportunities.

Growing pipeline A diversified pipeline across dosage forms offers multiple entry points for BD teams to identify adjacent sales opportunities, partnerships, or co-development deals in high-value therapeutic areas.

Financial velocity Current revenue range and a $23M funding position Solaris to pursue strategic partnerships, licensing, and contract manufacturing arrangements to scale operations and expand market reach.